Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes.
Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes.
复制标题
冠状动脉粥样硬化性心脏病的抗炎治疗：现有成功背后尚未解答的问题
DOI：
10.3389/fcvm.2020.631398
复制
发表时间：
2020
影响因子：
3.6
通讯作者：
Chen X
中科院分区：
文献类型：
--
作者：
Ma J;Chen X
冠状动脉粥样硬化性心脏病是严重威胁人类健康的疾病。2017年发表的Canakinumab抗炎血栓结局研究结果结束了关于冠状动脉粥样硬化性心脏病抗炎治疗的长期争论。除了白细胞介素1β单克隆抗体外，白细胞介素6受体拮抗剂和秋水仙碱在近3年的临床试验中也显示出令人兴奋的结果。然而，在这些成功的背后，仍然存在一些需要解决的问题。本文综述了白细胞介素1β抗体、白细胞介素6受体拮抗剂和秋水仙碱在抗炎治疗冠状动脉粥样硬化性心脏病中的成功及存在的问题。
Coronary atherosclerotic heart disease is a serious threat to human health. The results of the Canakinumab Anti-Inflammatory Thrombosis Outcome Study published in 2017 put an end to the perennial debate about the anti-inflammatory treatment of coronary atherosclerotic heart disease. In addition to interleukin 1β monoclonal antibody, interleukin 6 receptor antagonists and colchicine have also shown exciting results in clinical trials within the last 3 years. However, behind these successes, questions remain that need to be addressed. In this review, we summarize the successes and existing doubts of interleukin 1β antibodies, interleukin 6 receptor antagonists, and colchicine in the anti-inflammatory treatment of coronary atherosclerotic heart disease.